SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMMULOGIC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Lyle Abramowitz who wrote (32)5/7/1996 6:22:00 PM
From: Paul Getman   of 305
 
Hi Lyle,

Something to keep in mind regarding IMUL's tests is that they allow subjects to stay on their prescription antihistamines if they are using them during the trial. Since most people with severe allergies use some kind of antihistamine, the clinical significance of Allervax is reduced by the presence of the antihistamine. Yet, even with the antihistamine, Allervax significantly reduces allergy symptoms. Another point to keep in mind is that Allervax reduces all major allergy symptoms, while antihistamines often don't do so.

The market is currently valuing IMUL's technology at a ridiculously low amount: market value = $220 - $86M cash end '95 = $134M. That's a very, very low amount relative to its peers, especially for a company with two Phase III trials.

Also of note: the Wall Street Journal had a nice piece about new allergy treatments that mentioned IMUL this past Monday.

Paul
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News